MSR61 Comparative Efficacy of Osilodrostat Versus Pasireotide Subcutaneous and Pasireotide Long-Acting Release for the Treatment of Cushing's Disease – A Patient-Level Data Indirect Treatment Comparison Using Propensity Score Weighting

Autor: Tyas, E, Piacentini, A, Hemstock, M, Lilley, C, Lebbink, E, Matthijsse, S, Schmidt, F, Maman, K
Zdroj: In Value in Health July 2022 25(7) Supplement:S530-S530
Databáze: ScienceDirect
Externí odkaz: